Company: PTHS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001753926-25-001764
Chunk: 16

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 consolidated financial statements reflect all adjustments, consisting of
normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30,
2025 and 2024. Although management
believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the
information presented not misleading, certain information and footnote disclosures normally included in consolidated
financial statements that have been prepared in accordance U.S. GAAP have been omitted pursuant to the rules and regulations
of the SEC.

The
accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial
statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31,
2024, filed with the SEC on March 27, 2025. The interim results for the three and
nine months ended September 30, 2025 are
not necessarily indicative of the results to be expected for the year ending December 31, 2025 or
for any future interim periods.

Emerging
Growth Company

The
Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the
“Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered
public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared
effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and
comply with the requirements that apply to non-emerging growth companies